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ORIGINAL ARTICLE
Background: We have recently proposed to reclassify the pleo-
morphic subtype of epithelioid malignant pleural mesothelioma 
(MPM) as nonepithelioid (biphasic/sarcomatoid) histology because 
of its similarly poor prognosis. We sought to investigate whether 
preoperative maximum standardized uptake value (SUVmax) on 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) 
correlates with histologic subtype in MPM.
Methods: Clinical data were collected for 78 patients with MPM 
who underwent preoperative FDG-PET. We retrospectively clas-
sified the epithelioid tumors into five subtypes: trabecular, tubu-
lopapillary, micropapillary, solid, and pleomorphic. Tumors were 
categorized by SUVmax into two groups: low (<10.0) and high 
(≥10.0).
Results: The median overall survival of epithelioid tumors with 
high SUVmax (n = 12) was significantly shorter (7.1 months) 
than that of epithelioid tumors with low SUVmax (n = 54, 18.9 
months, p < 0.001) and comparable to nonepithelioid tumors (n = 
12, 7.2 months). Epithelioid tumors with pleomorphic subtype 
(n = 9) had marginally higher SUVmax (mean ± SD: 10.6 ± 5.9) 
than epithelioid nonpleomorphic subtype (n = 57, 6.5 ± 3.2, p = 
0.050), and were comparable to that of nonepithelioid tumors (n = 
12, 9.1 ± 4.8). Among the epithelioid tumors with high SUVmax 
(n = 12), 50% (n = 6) showed pleomorphic subtype. In contrast, 
among epithelioid tumors with low SUVmax (n = 54), 6% (n = 3) 
showed epithelioid pleomorphic subtypes (p = 0.001). A positive 
correlation between mitotic count and SUVmax was observed 
(r = 0.30, p = 0.010).
Conclusions: Pleomorphic subtype of epithelioid MPM showed 
higher SUVmax than the epithelioid nonpleomorphic subtype and 
was similar to nonepithelioid histology. Preoperative SUVmax on 
FDG-PET in epithelioid MPM can indicate patients with pleomor-
phic subtype with poor prognosis, supporting their reclassification 
as nonepithelioid.
(J Thorac Oncol. 2012;7: 1192–1197)
Key Words: Mesothelioma, Pleural neoplasm, Positron emission 
tomography, Pleomorphic.
Diffuse malignant pleural mesothelioma (MPM) is an uncommon but aggressive tumor with median survival of 
9 to 12 months despite multimodal therapy (surgery, chemo-
therapy, and radiation therapy).1 Histology and tumor, node, 
metastases (TNM) stage are the only standard predictors of 
survival.2–4 Although epithelioid MPM has a better prognosis 
than nonepithelioid (biphasic and sarcomatoid) tumors, prog-
nosis within epithelioid histology is variable. We have recently 
reported the prognostic utility of histologic subtyping in epi-
thelioid MPM, and proposed that the pleomorphic subtype 
should be reclassified as nonepithelioid histology because of 
similar clinical outcomes.5 However, to the best of our knowl-
edge, the biological reasons for this similarity in prognosis 
remain unexplored.
18F-fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) is a standard radiographic tool in clinical practice, 
which assesses the metabolic activity of tumor cells.6–8 In addi-
tion to facilitating prognosis, maximum standardized uptake 
value (SUVmax) on FDG-PET reflects histology in lung can-
cer. SUVmax is significantly lower in lung adenocarcinoma 
than in squamous cell carcinoma.9–11 To investigate the biology 
of the pleomorphic subtype in epithelioid MPM, our aim in 
this study was to determine the correlation between preopera-
tive SUVmax and histologic subtypes of epithelioid MPM. In 
addition, we investigated the correlation between SUVmax and 
tumor proliferation on the basis of mitotic count.
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PATIENTS AND METHODS
Patients
Tumor slides were available for 148 patients who received 
a diagnosis of MPM between 1998 and 2009 at Memorial 
Sloan-Kettering Cancer Center (MSKCC). Of these, 78 patients 
underwent FDG-PET before surgical resection. Fifty of 78 
patients (64%) underwent PET scans at MSKCC. Seventy-one 
patients (91%) were not treated with any chemotherapy before 
the PET scans. Clinical information was collected through a 
database maintained by the Thoracic Service, Department of 
Surgery at MSKCC. Institutional review board approval was 
obtained at MSKCC before the study began. There were 66 
patients with epithelioid tumors and 12 with nonepithelioid 
tumors (six biphasic and six sarcomatoid). Clinical variables 
recorded in the prospectively maintained database included 
age, sex, laterality, TNM stage, and surgical procedure. TNM 
staging was based on the reported imaging findings, the sur-
geon’s intraoperative findings, and the pathologic evaluation of 
the resected specimens using the 6th edition of the American 
Joint Commission on Cancer Staging Manual.12 All patients 
were followed until date of death or last follow-up.
Pathologic diagnosis was based on standard histologic, 
histochemical, and immunohistochemical criteria.13–15 As a 
positive marker of immunohistochemistry for MPM, we used 
standard immunohistochemical markers including calretinin, 
WT-1, cytokeratin 5/6, and D2-40. As negative markers for 
MPM, we used carcinoembryonic antigens, CD15, B72.3, 
BerEP4, and thyroid transcription factor-1. In addition, patho-
logic diagnosis was correlated with gross distribution of the 
tumor and absence of an intrapulmonary lesion on radiologic 
imaging.
Technique of FDG-PET
The following technique was used for PET scans per-
formed at MSKCC. Patients received 10 to 15 mCi (370–555 
MBq) of FDG intravenously. Patients were instructed to fast 
for 6 hours or more before injection; plasma-glucose levels 
were measured before imaging. Approximately 60 minutes 
after injection, torso images were acquired with either GE 
Advance (GE Medical Systems, Waukesha, WI) or HR plus 
(Siemens/CTI, Knoxville, TN) PET scanners. Beginning in 
November 2001, studies were also acquired on hybrid PET/
computed tomography (CT) imaging systems, including the 
Biograph (Siemens/CTI, Nashville, TN) and Discovery LS 
(GE Medical Systems, Waukesha, WI). The Biograph data 
was acquired in three-dimensional (3D) mode. All the other 
scanners used two-dimensional (2D) PET image acquisition. 
Discovery LS incorporates a PET Advance tomograph, and 
Biograph incorporates an HR plus PET tomograph. For PET/
CT, a low-dose CT scan was acquired first to allow for PET 
attenuation, correction, and anatomic localization of PET 
abnormalities. Each PET dataset was reconstructed for image 
display using iterative algorithms, with and without attenua-
tion correction. Experienced radiologists with specific exper-
tise in nuclear medicine interpreted PET imagery at the time 
of diagnosis. Uptake of FDG by tumor was quantified by PET 
region-of-interest analysis with the SUVmax. SUV was cal-
culated as:
SUV = 
(Decay-corrected activity[kBq]/tissue volume [ml] )
(Injected-FDG activity [kBq]/body weight [g])
Histologic Evaluation
All available hematoxylin and eosin–stained slides 
(median 7, range, 1–43 slides/case) of epithelioid MPM 
lesions were reviewed by a single pathologist (K.K.) for the 
purpose of this study, using an Olympus BX51 microscope 
(Olympus, Tokyo, Japan) with a standard eyepiece of 22 
mm diameter; problem cases were reviewed by two patholo-
gists (W.D.T. and K.K.). Histologic classification for epithe-
lioid MPM was done according to the 2004 World Health 
Organization criteria (<10% sarcomatoid component).15 
Epithelioid MPM comprised one or more of five histologic 
patterns,5 which were recorded in 5% increments: (1) trabe-
cular, (2) tubulopapillary, (3) micropapillary, (4) solid, and (5) 
pleomorphic. Tumors were classified as pleomorphic subtype 
when cytologic pleomorphism comprised at least 10% of the 
tumor.5 The remaining tumors were classified according to the 
predominant histologic patterns.
Mitoses were evaluated using high-power-field (HPF) 
at ×400 magnification (0.237 mm2 field of view) in the 50 HPF 
areas with the highest mitotic activities,16–19 and counted as an 
average of mitotic figures per 10 HPF. In the cases in which 
only small areas of viable tumor were available for review, the 
best attempt was made to assess the equivalent of 10 full HPFs 
of viable tumor for mitosis counting.17
We also recorded the following histological factors: 
presence of lymphatic or vascular invasion, necrosis (%), 
fibrosis (%), and myxoid change (%).
Statistical Analysis
Associations between clinicopathologic variables and 
histologic findings were analyzed using a Fisher’s exact test for 
categorical variables and Wilcoxon test for continuous vari-
ables. Overall survival (OS) after surgery was estimated using 
the Kaplan-Meier method, with patients censored if they were 
alive at the time of last follow-up. An analysis of time to recur-
rence (TTR) was restricted to patients who underwent surgery 
that was deemed to be a complete resection. Nonparametric 
group comparisons were performed using log-rank test. All 
p values were based on two-tailed statistical analysis and a 
p value < 0.05 was considered to indicate statistical signifi-
cance. All analyses were performed using SAS statistical soft-
ware (version 9.2; SAS Institute Inc., Cary, NC).
RESULTS
Clinicopathologic Demographics and Their 
Associations With OS
The clinicopathologic profile of 66 patients with epithe-
lioid MPM is outlined in Table 1. Median age was 63 (range, 
29–81); and 65% (n = 43) were men. The tumor involved 
the left pleura in 50% (n = 33) of the cases. Three patients 
(5%) were stage I, 16 (24%) were stage II, 33 (50%) were 
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stage III, and 14 (21%) were stage IV. Six patients (9%) were 
treated with chemotherapy before PET scan. Sixteen patients 
(24%) underwent pleurodesis before PET scans. Eleven of 
them (67%) underwent pleurodesis more than 1 month before 
PET. By surgical procedure, 37 (56%) underwent extrapleural 
pneumonectomy, 21 (32%) underwent pleurectomy-decorti-
cation, and the remaining eight (12%) had other procedures 
(three biopsies, four exploratory thoracotomies, and one pal-
liative pleurectomy). Lymphatic invasion was detected in 42% 
(n = 28) and vascular invasion in 20% (n = 13). By histologic 
subtype, nine tumors (14%) were pleomorphic and 57 (86%) 
were nonpleomorphic. In the six patients with epithelioid 
MPM, who underwent chemotherapy before PET scan, one 
tumor was pleomorphic and five were nonpleomorphic.
Median OS was 16.3 months. On univariate analyses, 
necrosis greater than or equal to 10% was associated with 
shorter OS (p = 0.002). No other clinicopathologic factors 
were significantly associated with OS.
SUVmax and Its Association With  
OS and TTR
Among the epithelioid MPM lesions, SUVmax ranged 
from 1.7 to 21.0 (median 6.3, mean ± SD 7.1 ± 3.9). Tumors 
were classified into two groups by SUVmax as previously 
reported: low SUVmax less than 10 and high SUVmax greater 
than or equal to 10.20,21 The median OS of patients with epi-
thelioid tumors with high SUVmax (n = 12) was significantly 
shorter (7.1 months) than that of patients with epithelioid 
tumors with low SUVmax (n = 54, 18.9 months, p < 0.001), 
and comparable to patients with nonepithelioid tumors (n = 
12, 7.2 months), as shown in Figure 1A.
We have recently proposed to reclassify the pleomor-
phic subtype of epithelioid MPM as nonepithelioid histology,5 
so we repeated our analysis of SUVmax in a cohort of patients 
with epithelioid MPM, excluding the nine pleomorphic 
cases. Among these 57 epithelioid cases, those with epithe-
lioid tumors with high SUVmax (n = 6) had a shorter median 
OS (5.6 months) than those with low SUVmax (n = 51, 19.4 
months, p = 0.005).
Recurrence was observed in 19 of the 44 patients with 
epithelioid tumors that underwent complete resection; the 
median TTR for patients with epithelioid tumors with high 
SUVmax (n = 7) was significantly shorter (14.4 months) than 
for low SUVmax (n = 37, 21.9 months, p = 0.047), as shown 
in Figure 1B.
Association Between SUVmax and Histology
Within the epithelioid MPM, tumors with pleomorphic 
subtype (n = 9) had the highest SUVmax (mean ± SD: 10.6 
± 5.9), followed by solid (n = 20, 6.5 ± 2.9), micropapillary 
(n = 10, 6.1 ± 2.8), tubulopapillary (n = 18, 6.7 ± 4.0), and 
trabecular (n = 9, 6.7 ± 3.0) (Fig. 2A). Epithelioid tumors with 
pleomorphic subtype had a marginally higher SUVmax than 
epithelioid nonpleomorphic subtype (n = 57, 6.5 ± 3.2, p = 
0.050). Nonepithelioid MPM (n = 12) seemed to have higher 
SUVmax (9.1 ± 4.8) compared to epithelioid tumors (n = 66, 
7.1 ± 3.9), although the difference was not significant (p = 0.160). 
TABLE 1. SUVmax Associations with Clinicopathologic 
Factors  in  Patients  With  Epithelioid  Malignant  Pleural 
Mesothelioma
Variables N SUVmax 
(mean ± SD) 
p 
Value
All patients 66 7.1 ± 3.9
Age 0.454
 ≤65 26 7.5 ± 4.3
 >65 40 6.3 ± 3.1
Sex 0.086
 Female 23 6.6 ± 4.8
 Male 43 7.3 ± 3.3
Laterality 0.640
 Left 33 7.5 ± 4.5
 Right 33 6.6 ± 3.1
T stage 0.530
 T1 6 6.1 ± 3.8
 T2 24 6.6 ± 3.7
 T3 25 8.1 ± 4.5
 T4 11 6.1 ± 2.6
N stage 0.240
 N0 42 6.8 ± 4.1
 N1 4 7.6 ± 2.5
 N2 20 7.5 ± 3.7
Stage 0.490
 I 3 6.8 ± 5.4
 II 16 6.5 ± 4.1
 III 33 7.6 ± 4.2
 IV 14 6.5 ± 2.4
Chemotherapy before PET 0.867
 Yes 6 7.1 ± 3.5
 No 60 7.1 ± 4.0
Pleurodesis before PET 0.805
 Yes 16 6.8 ± 3.7
 No 50 7.1 ± 4.0
Lymphatic invasion 0.750
 Absence 38 6.9 ± 3.9
 Presence 28 7.2 ± 3.9
Vascular invasion 0.054
 Absence 53 6.6 ± 3.6
 Presence 13 9.1 ± 4.5
Fibrosis 0.330
 <50% 43 7.6 ± 4.4
 ≥50% 23 6.1 ± 2.5
Necrosis 0.042
 <10% 59 6.6 ± 3.4
 ≥10% 7 10.8 ± 5.8
Myxoid 0.820
 <50% 61 7.0 ± 3.9
 ≥50% 5 7.2 ± 3.7
Histologic subtype 0.050
 Nonpleomorphic 57 6.5 ± 3.2
 Pleomorphic 9 10.6 ± 5.9
SUVmax, maximum standard uptake value; PET, positron emission tomography.
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However, SUVmax of nonepithelioid MPM was similar to 
that of epithelioid tumor with pleomorphic subtype and sig-
nificantly higher than that of epithelioid nonpleomorphic 
subtypes (p = 0.046) (Fig. 2B). Among the epithelioid tumors 
with high SUVmax (n = 12), 50% (n = 6) showed pleomor-
phic subtype. In contrast, among epithelioid tumors with low 
SUVmax (n = 54), 6% (n = 3) showed pleomorphic subtypes 
(p = 0.001).
Association Between SUVmax and 
Clinicopathologic Factors
Associations between SUVmax and clinicopathologic 
factors in patients with epithelioid MPM are outlined in Table 1. 
Among these factors, necrosis greater than or equal to 10% 
was significantly associated with higher SUVmax (p = 0.042). 
When examining mitotic count as a continuous variable, a 
moderate correlation between mitotic count and SUVmax 
was observed (r = 0.30, p = 0.010). Male sex (p = 0.086) 
and vascular invasion (p = 0.054) showed a tendency to have 
higher SUVmax. However, there were no associations among 
SUVmax and age, disease laterality, TNM stage, chemother-
apy before PET scan, pleurodesis before PET scan, lymphatic 
invasion, fibrosis, or myxoid change (greater than or equal to 
50%).
SUVmax of Patients Who Underwent PET 
Scan at MSKCC and Its Association With  
OS and Histology
Among the epithelioid MPM patients who underwent 
PET scan at MSKCC (n = 43), SUVmax ranged from 2.3 to 
16.5 (median 6.5, mean ± SD: 7.2 ± 3.4). Among the patients 
who underwent PET scan using Ge-68 transmission rods (GE 
Medical Systems) without CT (n = 14), SUVmax ranged from 
3.3 to 15.0 (median 6.6, mean ± SD: 7.2 ± 2.9). Among the 
patients who underwent PET/CT scan (n = 29), SUVmax 
ranged from 2.3 to 13.4 (n = 14, median 4.7, mean ± SD: 
5.6 ± 3.0) on Biograph and from 3.6 to 16.5 (n = 15, median 
8.3, mean ± SD: 8.6 ± 3.6) on Discovery LS.
In the patients who underwent PET scan at MSKCC 
(n = 50), who comprised two third of the total cohort, the 
median OS of patients with epithelioid tumors with high 
SUVmax (n = 7) was significantly shorter (8.9 months) than 
that of patients with epithelioid tumors with low SUVmax 
(n = 36, 19.4 months, p < 0.001), and comparable to patients 
with nonepithelioid tumors (n = 7, 6.9 months). SUVmax of 
tumors with epithelioid nonpleomorphic subtypes (n = 37, 
mean ± SD: 6.9 ± 2.9) was lower than that of epithelioid 
tumors with pleomorphic subtype (n = 6, 8.8 ± 5.5) and of 
nonepithelioid tumors (n = 7, 10.1 ± 5.4), although the small 
sample size did not allow for statistical analysis. Among the 
epithelioid tumors with high SUVmax (n = 7), 43% (n = 3) 
showed pleomorphic subtype. In contrast, among epithelioid 
tumors with low SUVmax (n = 36), 8% (n = 3) showed pleo-
morphic subtypes.
FIGURE 1. Overall survival (OS) and time to recurrence 
(TTR) by maximum standardized uptake value (SUVmax). 
A, The median OS of patients with epithelioid tumors 
with high SUVmax (n = 12) was significantly shorter (7.1 
months) than that of patients with epithelioid tumors 
with low SUVmax (n = 54, 18.9 months) and comparable to 
patients with nonepithelioid tumors (n = 12, 7.2 months). 
B, In 44 patients with completely resected epithelioid 
tumors, the median TTR for those with high SUVmax  
(n = 7) was significantly shorter (14.4 months) than that of 
patients with low SUVmax (n = 37, 21.9 months). SUVmax, 
maximum standardized uptake value.
FIGURE 2. Association between 
maximum standardized uptake 
value (SUVmax) and histology. A, 
Within the epithelioid tumors, pleo-
morphic subtype (n = 9) had the 
highest SUVmax (mean ± SD:  
10.6 ± 5.9), followed by solid (n = 
20, 6.5 ± 2.9), micropapillary  
(n = 10, 6.1 ± 2.8), tubulopapillary 
(n = 18, 6.7 ± 4.0), and trabecular 
(n = 9, 6.7 ± 3.0). B, SUVmax of 
nonepithelioid tumors (n = 12,  
9.1 ± 4.8) was similar to that of 
pleomorphic subtype and signifi-
cantly higher than that of epitheli-
oid nonpleomorphic subtype  
(n = 57, 6.5 ± 3.2). SUVmax, maxi-
mum standardized uptake value.
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DISCUSSION
Current preoperative therapeutic decisions of MPM are 
based on histologic type and the TNM stage. To account for 
the histological heterogeneity among epithelioid MPM, we 
have recently assessed the prognostic significance of five his-
tologic subtypes, and observed that the pleomorphic subtype 
resembles the clinical outcome of nonepithelioid (biphasic 
and sarcomatoid) histology more closely.5 To gain further 
insight into the biology of the pleomorphic subtype, we inves-
tigated whether the SUVmax reflects the histologic subtypes 
in epithelioid MPM. On the basis of mitotic count in patients 
with epithelioid MPM, we demonstrated that high SUVmax 
was associated not only with disease recurrence and OS, but 
also with increased proportion of pleomorphic subtype and 
proliferative activity.
Pleomorphic subtype is defined as having more than10% 
of the tumor demonstrating pleomorphism.5 Accurately iden-
tifying these patients before deciding on appropriate therapeu-
tic management is difficult because the small proportion of 
pleomorphism may not be obvious on small diagnostic biopsy 
samples. Yet, given their poor prognosis (median OS = 8.1 
months),5 the ability to recognize this population is critical to 
clinical decision-making. In the current study, we observed that 
the nine epithelioid tumors with pleomorphic subtype were 
characterized by having higher SUVmax (mean SUVmax = 
10.6) compared to epithelioid nonpleomorphic subtypes 
(mean SUVmax = 6.1–6.7) (Fig. 2A). Among the patients with 
epithelioid MPM with SUVmax greater than 10, half had the 
pleomorphic subtype, whereas for those with SUVmax less 
than 10, the majority (94%) had the nonpleomorphic subtype. 
Though it is difficult to precisely correlate the pleomorphic 
area on microscopic examination to the site of SUVmax on 
FDG-PET, the association we observed may help in preopera-
tive identification of the pleomorphic subtype.
Furthermore, we observed a similarity in the SUVmax 
of the pleomorphic subtype (mean SUVmax = 10.6) and the 
nonepithelioid histology (mean SUVmax = 9.1) (Fig. 2B). In 
our previous report we demonstrated the resemblance in out-
comes between the pleomorphic subtype and the nonepithe-
lioid histology (the pleomorphic subtype experienced median 
OS of 8.1 months compared to 7.0 months and 3.0 months for 
biphasic and sarcomatoid, respectively).5 Our current obser-
vation provides radiographic evidence that the pleomorphic 
subtype resembles the nonepithelioid MPM more closely than 
the epithelioid histology, and further strengthens our proposal 
to reclassify the pleomorphic subtype under the nonepithe-
lioid histology.
High FDG uptake has been shown to correlate with 
decreased survival in patients with MPM.20–23 However, these 
studies were heterogeneous in morphology because they 
included nonepithelioid tumors. Therefore, the prognostic util-
ity of FDG uptake was unclear in a uniform cohort that com-
prised epithelioid histology. Within our cohort of 66 patients 
with epithelioid MPM, a cutoff of SUVmax 10 significantly 
stratified OS, and this finding remained significant even after 
excluding patients with pleomorphic subtype.
In our study, 24% of epithelioid MPM patients under-
went pleurodesis before PET scans. Although the prolonged, 
marked hypermetabolic pleural activity associated with pleu-
rodesis may potentially limit PET-scan evaluation, the pleu-
ral SUVmax in the epithelioid MPM patients who underwent 
pleurodesis before PET scan showed no significant difference 
from that of the patients with no prior pleurodesis.
One limitation of the current study is that the PET scans 
were performed at multiple locations. Because of the rarity of 
MPM, it is difficult to obtain a large number of scans at a sin-
gle location. Nevertheless, two thirds of the scans in this study 
were performed at the same location. To validate our findings 
with a more uniform group of patients, we performed the sub-
sequent analysis on the patients who underwent PET scan at 
MSKCC. In this group, the SUVmax remained significant in 
stratifying OS, and the epithelioid tumor with pleomorphic 
subtype demonstrated a higher SUVmax than in epithelioid 
nonpleomorphic subtypes.
One more limitation of our study is that the PET scans 
were performed by four different scanners at MSKCC, 
and the SUV differences were observed by the different 
scanners, attenuation corrections, and acquisition models. 
Although the use of four different scanners is a potential 
limitation of this study, our correlations are significant 
despite the limitations of our study—differences in CT ver-
sus rod-source attenuation correction,24 and differences in 
acquisition of data in 2D or 3D models.25 On a more positive 
note, however, the fact that we were able to detect statisti-
cally significant associations between SUVmax versus OS 
and histology, despite using different scanners, may sug-
gest that (1) our results are generalizable to other medical 
centers using different scanners than ours and (2) the true 
correlation between SUVmax versus OS and histology may 
be underestimated by our results, presuming that using dif-
ferent scanners will weaken such correlation rather than 
strengthen it. The previous report suggested the SUV dif-
ferences by the different acquisition models (2D or 3D).25 
In our study, the Biograph data were acquired in 3D mode, 
and all the other scanners used 2D PET image acquisition. 
Again, although these technical differences may weaken 
the ability to detect the correlations that we reported in this 
study, we detected the correlations despite these technical 
limitations, not because of them.
Although future studies should normalize SUVmax by 
different scanners, our findings confirm its prognostic value. 
In a recent report, Nowak et al.26 proposed a prognostic model 
that incorporates total glycolytic volume (TGV) on FDG-PET 
to account for the tumor volume in addition to the metabolic 
activity. Interestingly, in their cohort of 89 patients, TGV was 
prognostic whereas SUVmax was not. We did not record TGV 
in the current study.
In addition to prognosis, SUVmax correlates with a 
higher proliferation index in lung cancer.7,27 However, the cor-
relation between SUVmax and proliferative factors, such as 
Ki-67 labeling index and mitotic count, has not been investi-
gated in MPM. In our study, higher SUVmax showed a cor-
relation with higher mitotic count, demonstrating that FDG 
uptake by MPM tumor cells reflects proliferative activity. 
We also demonstrated that necrosis correlates with higher 
SUVmax. These findings confirm that SUVmax reflects tumor 
biology in addition to having prognostic value.
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In conclusion, we have demonstrated in this study a 
radiologic–pathologic correlation in epithelioid MPM through 
comparison using a noninvasive imaging modality that mea-
sures tumor metabolism (SUVmax on FDG-PET) and histo-
logic characterization on microscopic examination (histologic 
subtype). We observed that (1) high SUVmax correlates with 
pleomorphic subtype in epithelioid MPM, thus providing 
radiologic resemblance of the pleomorphic subtype with the 
nonepithelioid tumors, and (2) epithelioid MPM with high 
SUVmax should be considered as having a poorer progno-
sis, similar to nonepithelioid tumors. As this is a retrospec-
tive study, these findings should be validated prospectively. 
Nonetheless, our findings emphasize the importance of a mul-
tidisciplinary approach in both predicting patient outcomes 
and better understanding of a heterogeneous disease such 
as MPM.
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